Skip to main content
    H

    Haemonetics Corporation (HAE)

    Official site

    HEALTHCARE • MEDICAL DEVICES • NYSE

    $121.40
    -1.54 (-1.25%)

    Market Cap: $5.60B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Haemonetics Corporation (HAE) P/E Ratio & Valuation History

    Updated Nov 17, 2026. Multiples are computed from end-of-day prices, company filings and consensus analyst estimates.

    Haemonetics (HAE) trades at 23.9x trailing earnings and 4.0x sales. Its P/E of 23.9x is above its 5-year median of 21.0x. Its forward P/E is 23.0x. The median P/E across 9 similar companies is 31.1x.

    Current Multiples

    Its forward P/E is below its trailing P/E, which implies earnings per share about 3.9% higher over the next year. Its free cash flow yield is 5.4%.

    MultipleValue
    P/E (trailing)23.9x
    Forward P/E23.0x
    Price to sales4.0x
    Price to book6.1x
    EV/EBITDA25.3x
    Price to FCF18.5x
    EV/FCF21.4x
    PEG1.9
    FCF yield5.4%
    As of Nov 17, 2026

    Historical Medians

    Against its 10-year medians, its P/E is 10.2% below 26.6x, its P/S is 14.3% above 3.5x and its P/B is 24.5% above 4.9x.

    MultipleCurrent5-year median10-year median
    P/E23.9x21.0x26.6x
    P/S4.0x3.1x3.5x
    P/B6.1x4.4x4.9x
    Medians of month-end values through Oct 2026: 60 months (5-year) and 120 months (10-year).

    Valuation History

    Over the 10 year ends shown, its P/E ranged from 16.3x in 2025 to 46.0x in 2020. 2025 was the lowest of those years.

    Year endPriceP/EP/SP/B
    2025$80.1516.3x2.9x4.1x
    2024$78.0818.5x2.9x4.3x
    2023$85.5122.2x3.4x4.6x
    2022$78.6527.0x3.6x5.1x
    2021$53.0422.1x2.8x3.7x
    2020$118.7546.0x6.8x8.4x
    2019$114.9035.6x5.9x10.1x
    2018$100.0545.3x5.5x8.0x
    2017$58.0831.9x3.4x3.7x
    2016$40.2026.6x2.3x2.7x
    Each year's multiples use the split-adjusted closing price of that year's last trading day over trailing per-share results as reported; periods with losses are left out.

    GNG Valuation

    GNG viewFairly valued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About HAE

    What is HAE's forward P/E ratio?

    Haemonetics has a forward P/E ratio of 23.0x.

    Is HAE stock overvalued?

    GNG's valuation label for HAE is Fairly valued. Its P/E of 23.9x compares with a median of 31.1x across 9 similar companies.

    What is HAE's price to sales ratio?

    Haemonetics has a price to sales ratio of 4.0x.

    What is Haemonetics's average P/E ratio over 5 years?

    Haemonetics's median P/E over the last 5 years is 21.0x, from 60 month-end values through Oct 2026.

    What is HAE's PEG ratio?

    Haemonetics has a PEG ratio of 1.9.